- Conditions
- Atrial Fibrillation, Percutaneous Coronary Intervention
- Interventions
- rivaroxaban 2.5 mg, rivaroxaban 15 mg, rivaroxaban 10 mg, aspirin (ASA), vitamin K antagonist (VKA), clopidogrel, prasugrel, ticagrelor
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 86
- States / cities
- Huntsville, Alabama • Los Alamitos, California • Mission Viejo, California + 83 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Coronary Artery Disease
- Interventions
- Ticagrelor 90 mg, Prasugrel 10 mg
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Coronary Artery Disease, Platelet Aggregation Inhibitors, PCI- Percutaneous Coronary Intervention
- Interventions
- Loading Dose Arm, Maintenance Dose Arm
- Drug
- Lead sponsor
- St. Francis Hospital, New York
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Roslyn, New York
- Conditions
- Coronary Artery Disease
- Interventions
- PROMUS Coronary Stent System, PROMUS Element Coronary Stent System, Aspirin, Thienopyridine
- Device · Drug
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
- Conditions
- Bleeding Complications
- Interventions
- Clopidogrel, Prasugrel, Tricagrelor
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Migraine, Patent Foramen Ovale, PFO - Patent Foramen Ovale
- Interventions
- Actual device PFO closure, Thienopyridine (clopidogrel or prasugrel), Sham device PFO closure
- Device · Drug
- Lead sponsor
- W.L.Gore & Associates
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Los Angeles, California • Santa Barbara, California + 11 more
- Conditions
- Coronary Artery Disease
- Interventions
- Prasugrel, Clopidogrel, Placebo for Prasugrel, Placebo for Clopidogrel
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 4
- States / cities
- Jacksonville, Florida • Worcester, Massachusetts • Ann Arbor, Michigan + 1 more
- Conditions
- Covid19
- Interventions
- theraputic heparin, prophylactic heparin, P2Y12, Crizanlizumab Injection, SGLT2 inhibitor
- Drug
- Lead sponsor
- Matthew Neal MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,591 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more
- Conditions
- Coronary Artery Disease
- Interventions
- Prasugrel
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Acute Coronary Syndrome
- Interventions
- Acetylsalicylic acid, Rivaroxaban, Clopidogrel, Ticagrelor
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,037 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 49
- States / cities
- Alexander City, Alabama • Banning, California • Sylmar, California + 46 more
- Conditions
- Coronary Artery Disease
- Interventions
- prasugrel, clopidogrel
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- Jacksonville, Florida • Baltimore, Maryland • Cincinnati, Ohio
- Conditions
- Antiplatelet
- Interventions
- Prasugrel 10mg, Clopidogrel 75mg
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 43,864 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Coronary Artery Disease
- Interventions
- Prasugrel, Clopidogrel
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Cincinnati, Ohio
- Conditions
- Sickle Cell Disease
- Interventions
- Prasugrel, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 20
- States / cities
- Oakland, California • Palo Alto, California • Hartford, Connecticut + 16 more
- Conditions
- Healthy
- Interventions
- ACT-246475, Clopidogrel, Prasugrel, Placebo, Ticagrelor
- Drug
- Lead sponsor
- Viatris Innovation GmbH
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Platelet Dysfunction, Von Willebrand Diseases, Healthy, Congenital Platelets Abnormality
- Interventions
- T-TAS 01 PL Chip, PFA-100 Col/Epi and Col/ADP
- Diagnostic Test
- Lead sponsor
- Hikari Dx, Inc.
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 307 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 5
- States / cities
- San Francisco, California • Iowa City, Iowa • Baltimore, Maryland + 2 more
- Conditions
- Coronary Arteriosclerosis, Acute Coronary Syndromes
- Interventions
- Prasugrel, Clopidogrel
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13,619 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Acute Myocardial Infarction
- Interventions
- Not listed
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Coronary Artery Disease
- Interventions
- Prasugrel, Ticagrelor
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Cardiovascular Disease
- Interventions
- Not listed
- Lead sponsor
- Medco Health Solutions, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 4,471 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Franklin Lakes, New Jersey
- Conditions
- Coronary Arterial Disease (CAD), Peripheral Vascular Disease
- Interventions
- Aspirin, P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
- Drug
- Lead sponsor
- Ochsner Health System
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Coronary Arteriosclerosis, Acute Coronary Syndrome
- Interventions
- prasugrel 10 mg, clopidogrel, prasugrel placebo, prasugrel 60 mg, clopidogrel placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 9
- States / cities
- Jacksonville, Florida • Baltimore, Maryland • Worcester, Massachusetts + 6 more
- Conditions
- Cardiovascular Diseases, Heart Diseases
- Interventions
- Prasugrel (CS-747), Clopidogrel
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 905 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more